Street Calls of the Week
Director Paul Schimmel of aTyr Pharma Inc (NASDAQ:ATYR), currently valued at $93.77 million, recently purchased shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission. The purchases, which totaled $911,801, were executed in two tranches. The timing appears strategic, as InvestingPro data shows the stock has gained 34% in the past week, though trading with high volatility.
On October 8, 2025, Schimmel acquired 682,001 shares at a weighted average price of $0.898, with prices ranging from $0.8536 to $0.95 per share. The following day, October 9, 2025, he bought an additional 317,999 shares at a weighted average price of $0.9414, with prices ranging from $0.93 to $0.95 per share. These purchases come as InvestingPro analysis indicates the stock is in oversold territory, with the company maintaining more cash than debt on its balance sheet.
Following these transactions, Schimmel directly owns 8,890 shares and indirectly owns 2,092,166 shares of aTyr Pharma Inc. common stock. For deeper insights into insider trading patterns and 12 additional key metrics, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, aTyr Pharma reported additional findings from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis patients. The company highlighted improvements in the Fatigue Assessment Scale Total Score and King’s Sarcoidosis Questionnaire-General Health score at week 48 for patients receiving the 5.0 mg/kg treatment compared to placebo. However, the trial failed to meet its primary endpoint, leading to multiple downgrades from analysts. Lucid Capital Markets downgraded aTyr Pharma from Buy to Neutral, citing uncertainty in the regulatory and clinical outlook and reducing its price target significantly. Similarly, Jones Trading downgraded the stock to Hold, pointing out unexpected outcomes in the trial’s placebo arm. H.C. Wainwright also downgraded aTyr Pharma to Neutral after the trial’s failure to achieve its primary goal. Cantor Fitzgerald followed suit, downgrading the stock from Overweight to Neutral due to the trial’s inability to demonstrate statistically significant results in reducing mean steroid dose. These developments reflect the challenges aTyr Pharma faces in its clinical efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.